Biophytis S.A. (ALBPS) - Total Liabilities
Based on the latest financial reports, Biophytis S.A. (ALBPS) has total liabilities worth €14.44 Million EUR (≈ $16.88 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ALBPS strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Biophytis S.A. - Total Liabilities Trend (2012–2024)
This chart illustrates how Biophytis S.A.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Biophytis S.A. total assets.
Biophytis S.A. Competitors by Total Liabilities
The table below lists competitors of Biophytis S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sodas Sodyum Sanayi AS
IS:SODSN
|
Turkey | TL9.87 Million |
|
Agrogalaxy Participacoes SA
SA:AGXY3
|
Brazil | R$2.40 Billion |
|
Smooth Rock Ventures Corp
V:SMRV
|
Canada | CA$74.60K |
|
Ganga Forging Limited
NSE:GANGAFORGE
|
India | Rs302.43 Million |
|
Yari Minerals Ltd
AU:YAR
|
Australia | AU$569.99K |
|
Vp plc
LSE:VP
|
UK | GBX334.73 Million |
|
Begbies Traynor Group PLC
LSE:BEG
|
UK | GBX83.60 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Biophytis S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ALBPS equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.08 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biophytis S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biophytis S.A. (2012–2024)
The table below shows the annual total liabilities of Biophytis S.A. from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €16.60 Million ≈ $19.41 Million |
+4.76% |
| 2023-12-31 | €15.85 Million ≈ $18.53 Million |
-33.68% |
| 2022-12-31 | €23.90 Million ≈ $27.94 Million |
-21.79% |
| 2021-12-31 | €30.56 Million ≈ $35.72 Million |
+49.95% |
| 2020-12-31 | €20.38 Million ≈ $23.82 Million |
-19.13% |
| 2019-12-31 | €25.20 Million ≈ $29.46 Million |
+69.61% |
| 2018-12-31 | €14.86 Million ≈ $17.37 Million |
+212.04% |
| 2017-12-31 | €4.76 Million ≈ $5.57 Million |
+22.90% |
| 2016-12-31 | €3.87 Million ≈ $4.53 Million |
+109.34% |
| 2015-12-31 | €1.85 Million ≈ $2.16 Million |
+22.09% |
| 2014-12-31 | €1.52 Million ≈ $1.77 Million |
+46.15% |
| 2013-12-31 | €1.04 Million ≈ $1.21 Million |
-4.36% |
| 2012-12-31 | €1.08 Million ≈ $1.27 Million |
-- |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement w… Read more